We have known for some time that cancer is not a static, monolithic disease. Instead, we now think of cancer as heterogeneous. Each patient’s cancer may arise from widely dissimilar origins, even in patients with the same type of tumor. Several studies in the last year have spelled out the extent of this diversity, which … Continue reading “Oncology’s Future: Liquid Biopsies and the Heterogeneity of Cancer”
Author: Murali Prahalad
Murali Prahalad has been the president and CEO of San Diego-based Epic Sciences since 2013. He has more than 14 years of experience in technology and life science companies. Prior to joining Epic, he was vice president of corporate strategy at Life Technologies, now part of Thermo Fisher Scientific, where he helped shape the organic and inorganic investment priorities for research tools, clinical diagnostics, and applied market portfolios. After joining Life Technologies in 2005, his experience ranged from mergers and acquisitions to in-licensing and general management, including large businesses that spanned everything from genomics to cell biology. As a general manager, he had to grow revenue and profit by building stronger teams, driving innovation, and managing operations for both consumable and instrument portfolios. Prior to Life Technologies, he was vice president of business development at Sequenom, another San Diego company. Prahalad also is proficient and literate in several languages including Japanese, French, and Kannada. He received a doctorate in biochemistry and molecular pharmacology, and a masters degree in medical sciences from Harvard University. He received his bachelors degree with honors in cellular and molecular biology and economics from the University of Michigan.